tradingkey.logo

PureTech Health PLC

PRTC
16.790USD
+0.040+0.24%
Market hours ETQuotes delayed by 15 min
4.03BMarket Cap
93.63P/E TTM

PureTech Health PLC

16.790
+0.040+0.24%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of PureTech Health PLC

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PureTech Health PLC's Score

Industry at a Glance

Industry Ranking
256 / 501
Overall Ranking
460 / 4682
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
46.000
Target Price
+181.52%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

PureTech Health PLC Highlights

StrengthsRisks
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.83M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 101.38, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 355.84K shares, decreasing 14.97% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

No financial score is currently available for PureTech Health PLC. The Biotechnology & Medical Research industry's average is 6.92. Its latest quarterly revenue reached 4.54M, representing a year-over-year increase of 2422.22%, while its net profit experienced a year-over-year increase of 334.15%.

Score

Industry at a Glance

Previous score
0.00
Change
0

Financials

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

Operational Efficiency

Growth Potential

Shareholder Returns

PureTech Health PLC's Company Valuation

Currency: USD Updated: 2025-10-27

No valuation score is currently available for PureTech Health PLC. The Biotechnology & Medical Research industry's average is 6.98. Its current P/E ratio is 101.38, which is 150.66% below the recent high of 254.13 and 100.00% above the recent low of 0.00.

Score

Industry at a Glance

Previous score
0.00
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 256/501
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-10-27

The current earnings forecast score of PureTech Health PLC is 10.00, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The average price target for PureTech Health PLC is 46.00, with a high of 46.00 and a low of 46.00.

Score

Industry at a Glance

Previous score
10.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.
No Data

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The current price momentum score of PureTech Health PLC is 9.68, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 24.94 and the support level at 5.71, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.67
Change
0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.086
Sell
RSI(14)
51.542
Neutral
STOCH(KDJ)(9,3,3)
85.733
Buy
ATR(14)
3.020
High Vlolatility
CCI(14)
32.076
Neutral
Williams %R
7.172
Overbought
TRIX(12,20)
-0.582
Sell
StochRSI(14)
96.391
Overbought
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
13.581
Buy
MA10
15.110
Buy
MA20
15.936
Buy
MA50
16.581
Buy
MA100
16.830
Sell
MA200
17.325
Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Pentwater Capital Management LP
50.00K
+48.99%
Millennium Management LLC
23.86K
-46.88%
Diadema Partners LP
7.32K
--
Persistent Asset Partners Limited
1.69K
--
Geode Capital Management, L.L.C.
770.00
--
Dimensional Fund Advisors, L.P.
316.00
--
UBS Financial Services, Inc.
20.00
--
Fidelity Management & Research Company LLC
1.28K
--
Atlantic Union Bankshares Corporation
115.00
--
Portolan Capital Management, L.L.C.
27.80K
+133.87%
1
2

Risk Assessment

Currency: USD Updated: 2025-10-27

No risk assessment score is currently available for PureTech Health PLC. The Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
0.00
Change
0
Beta vs S&P 500 index
1.04
VaR
--
240-Day Maximum Drawdown
+100.00%
240-Day Volatility
--

Return

Best Daily Return
60 days
--
120 days
--
5 years
--
Worst Daily Return
60 days
-100.00%
120 days
-100.00%
5 years
--
Sharpe Ratio
60 days
--
120 days
--
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+100.00%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-0.05
3 years
-0.15
5 years
-0.14
Skewness
240 days
--
3 years
--
5 years
--

Volatility

Realised Volatility
240 days
--
5 years
--
Standardised True Range
240 days
+5.99%
5 years
+19.53%
Downside Risk-Adjusted Return
120 days
--
240 days
--
Maximum Daily Upside Volatility
60 days
--
Maximum Daily Downside Volatility
60 days
--

Liquidity

Average Turnover Rate
60 days
+0.03%
120 days
--
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--

Peer Comparison

Biotechnology & Medical Research
PureTech Health PLC
PureTech Health PLC
PRTC
4.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of PureTech Health PLC?

The TradingKey Stock Score provides a comprehensive assessment of PureTech Health PLC based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of PureTech Health PLC’s performance and outlook.

How do we generate the financial health score of PureTech Health PLC?

To generate the financial health score of PureTech Health PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects PureTech Health PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of PureTech Health PLC.

How do we generate the company valuation score of PureTech Health PLC?

To generate the company valuation score of PureTech Health PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare PureTech Health PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of PureTech Health PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of PureTech Health PLC.

How do we generate the earnings forecast score of PureTech Health PLC?

To calculate the earnings forecast score of PureTech Health PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on PureTech Health PLC’s future.

How do we generate the price momentum score of PureTech Health PLC?

When generating the price momentum score for PureTech Health PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of PureTech Health PLC’s prices. A higher score indicates a more stable short-term price trend for PureTech Health PLC.

How do we generate the institutional confidence score of PureTech Health PLC?

To generate the institutional confidence score of PureTech Health PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about PureTech Health PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of PureTech Health PLC.

How do we generate the risk management score of PureTech Health PLC?

To assess the risk management score of PureTech Health PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of PureTech Health PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of PureTech Health PLC.
KeyAI